CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place - Episode 4
Strategic Timing for CAR T in R/R MM: The Importance of Early Referral
Experts discuss when physicians should consider referring patients to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (R/R MM). They emphasize the importance of early referral and access to CAR T in earlier lines of therapy while commenting on the similarities and differences in referral timing, particularly for patients treated in the community.
Video Player is loading.
Video content above is prompted by the following:
- When should physicians start thinking about referring their patients to CAR T? Why is early referral or allowing access to CAR T in earlier lines of therapy critical for patients with R/R MM?
- Please comment on any similarities and/or differences regarding the ideal or most appropriate timing for CAR T referral, especially for those patients treated in the community.
Related Content:
